Natera (NTRA) president sells 2,213 shares to cover RSU tax obligations

Rhea-AI Filing Summary

Natera, Inc. executive Solomon Moshkevich, President of Clinical Diagnostics, reported small insider sales of common stock tied to RSU vesting. On January 27, 2026, he sold 1,013 shares at $240.5313, and on January 28, 2026 he sold 1,200 shares at $237.6624.

The filing states both sales were made to satisfy tax withholding and remittance obligations from restricted stock unit vesting, under a written instruction intended to meet Rule 10b5-1(c) affirmative defense conditions. After these transactions, he directly owns 142,486 shares of Natera common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moshkevich Solomon

(Last) (First) (Middle)

C/O NATERA, INC.

13011 MCCALLEN PASS BUILDING A SUITE 100

(Street)

AUSTIN TX 78753

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Natera, Inc. [ NTRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT, CLINICALDIAGNOSTICS

3. Date of Earliest Transaction (Month/Day/Year)
01/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/27/2026		S		1,013(1)	D	$240.5313	143,686	D
Common Stock	01/28/2026		S		1,200(2)	D	$237.6624	142,486	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 26, 2024.

2. The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 27, 2023.

	/s/ Tami Chen, Attorney-in-Fact	01/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Natera (NTRA) report for Solomon Moshkevich?

Natera reported that executive Solomon Moshkevich sold 1,013 shares on January 27, 2026 and 1,200 shares on January 28, 2026. Both transactions involved Natera common stock and were disclosed on a Form 4 insider trading report.

How many Natera shares did Solomon Moshkevich sell and at what prices?

Solomon Moshkevich sold 1,013 Natera common shares at $240.5313 on January 27, 2026, and 1,200 shares at $237.6624 on January 28, 2026. These transactions were reported as open-market sales of common stock.

Why did Natera executive Solomon Moshkevich sell shares according to the Form 4?

The Form 4 states the sales were made to satisfy tax withholding and remittance obligations related to vesting restricted stock units. They were executed under a written instruction intended to meet the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.

How many Natera shares does Solomon Moshkevich own after these transactions?

After the reported sales, Solomon Moshkevich directly owns 142,486 shares of Natera common stock. This figure reflects his beneficial ownership following the January 27 and January 28, 2026 transactions disclosed in the Form 4 filing.

What is Solomon Moshkevich’s role at Natera mentioned in the Form 4?

The Form 4 identifies Solomon Moshkevich as an officer of Natera with the title “President, Clinical Diagnostics.” This indicates he is a senior executive responsible for Natera’s clinical diagnostics segment and subject to Section 16 insider reporting rules.

What does the Form 4 say about Rule 10b5-1(c) in relation to these Natera trades?

The filing explains the sales were made under a written instruction intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. This language indicates the trades followed a pre-established plan tied to RSU vesting and tax obligations.